BIO Comments: Administering the Hatch-Waxman Amendments: Ensuring a Balance Between Innovation and Access
December 5, 2017
The Biotechnology Innovation Organization (“BIO”) welcomes the opportunity to submit written comments to supplement our previous live testimony to the FDA’s open docket on the Hatch-Waxman Amendments: Ensuring a Balance Between Innovation and Access. BIO appreciated the opportunity to participate in FDA’s July 18th public meeting on this important topic and we are happy to supplement the record with these written comments.
BIO also supplemted the comments we filed on September 19, 2017 to better inform the Docket on Administering the Hatch-Waxman Amendments: Ensuring a Balance Between Innovation and Access. 1 Following submission of our comments pursuant to the initial closing date, other stakeholder comments were filed that raise issues of significant concern to BIO and our members. To ensure stakeholder interests in this issue are fully and accurately reflected, BIO submits these supplemental comments for FDA’s consideration
Download Full Comments Below
Comment From Biotechnology Innovation Organization BIO (1)
Bio Comments on Administering the Hatch-Waxman Amendments: Ensuring a Balance Between Innovation and Access
Dear Colleagues,This month marks my one-year anniversary as BIO’s CEO. Like most of us in biotech, this post has been a labor of love. At no time in my 25-year career in this industry have I ever witnessed such awe-inspiring science. Today, we…
Re: BIO Comments on Office of Management and Budget (OMB) Statistical Policy Directive No. 8 North American Industry Classification System (NAICS)-Request forComments on Possible Revisions for 2027 (USBC–2024–0032)Dear Ms. Orvis,The Biotechnology…
Under the 340B program, participating manufacturers must offer 340B pricing on their covered outpatient drugs by covered entities, as a condition of having those drugs federally payable under Medicare Part B and Medicaid. Critically, Congress…
The Biotechnology Innovation Organization (“BIO”) welcomes the opportunity to submit written comments to supplement our previous live testimony to the FDA’s open docket on the Hatch-Waxman Amendments: Ensuring a Balance Between Innovation and Access. BIO appreciated the opportunity to participate in FDA’s July 18th public meeting on this important topic and we are happy to supplement the record with these written comments.
BIO also supplemted the comments we filed on September 19, 2017 to better inform the Docket on Administering the Hatch-Waxman Amendments: Ensuring a Balance Between Innovation and Access. 1 Following submission of our comments pursuant to the initial closing date, other stakeholder comments were filed that raise issues of significant concern to BIO and our members. To ensure stakeholder interests in this issue are fully and accurately reflected, BIO submits these supplemental comments for FDA’s consideration